trending Market Intelligence /marketintelligence/en/news-insights/trending/5dddTBsg6V5n-FFmCzbbtw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

CEO of Novartis' Sandoz unit to step down; interim replacement named

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

CEO of Novartis' Sandoz unit to step down; interim replacement named

Novartis AG said Richard Francis is stepping down as CEO of Sandoz, its generics business, effective March 31.

SNL Image

Sandoz CEO Richard Francis
Source: Sandoz

Francis, who has held the position since 2014, is also leaving his role as a member of Novartis' executive committee.

Sandoz is undertaking an 18-month turnaround period to shed various operations around the globe and become an autonomous unit within Basel, Switzerland-based Novartis.

"Richard has decided that for personal reasons he cannot commit to stay with Sandoz until the transformation is completed," Novartis CEO Vas Narasimhan said.

Francesco Balestrieri, Sandoz's region head for Europe, was named ad-interim CEO of the unit. He has been with Novartis for 25 years, the last eight of which he led commercial operations in generics.